tonsil, DLBCL, follicle center lymphoma
cytoplasmic and nuclear
Regulatory status: IVD, FDA Class I
8462-C010: RTU, 10 capsules; 1 pack
8462-M250: RTU, 250 tests, 1 cartridge; 1 unit
BOB.1 is a B-cell specific coactivator and interacts with OCT.1 and OCT.2 transcription factors. The expression of BOB.1 is limited largely to mature B-cells in germinal centers and mantle zones, as well as plasma cells. The expression of BOB.1 in B-cell tumors is variable. Lymphocyte predominant (LP) cells in nodular lymphocyte predominant Hodgkin lymphoma are BOB.1 positive. In B-cell lymphomas, the highest expression levels for BOB.1 are in follicle center lymphomas, diffuse large B-cell lymphomas (DLBCL) and Burkitt lymphomas.
The neoplastic cells in this classical Hodgkin lymphoma show no, or only very weak, nuclear staining
Scattered B-cells among the ducts and lobules of this benign breast specimen show strong nuclear reactivity for BOB.1.
The neoplastic cells of this diffuse large B-cell lymphoma show moderate to strong cytoplasmic and nuclear staining for BOB.1.